GCG and diabetes mellitus: While the intrinsic GLP-1 peptide has a short half-life, synthetic GLP-1 receptor agonists typically have longer half-lives and bind with similar affinity to the GLP-1 receptor, thereby acting to prevent hyper- and hypo-glycaemia in patients with diabetes [114].